Key result
Targeted ASCVD prevention in psychiatric primary care may mitigate excess cardiovascular morbidity and mortality.
Why the study?
Persons with psychiatric diagnoses are at disproportionately high risk for cardiovascular disease mediated by the cardiovascular-kidneymetabolic syndrome, and behavioral initiatives alone often fall short in achieving attainable prevention goals.
Does incorporating GLP-1 receptor agonists, statins, and CACS-guided low-dose aspirin into primary care reduce ASCVD morbidity and mortality in patients with psychiatric diagnoses?
Does incorporating GLP-1 receptor agonists, statins, and CACS-guided low-dose aspirin into primary care reduce ASCVD morbidity and mortality in patients with psychiatric diagnoses?
Integrating modern pharmacological and imaging-guided primary cardiovascular prevention strategies into the routine care of psychiatric patients may help reduce their disproportionately high burden of ASCVD morbidity and mortality.
Answers are grounded in this paper and cite their sources.
Should not yet change psychiatric primary care; leaves open whether integrated GLP-1 agonists and CACS-guided therapy reduce ASCVD events.
Persons with psychiatric diagnoses are at a disproportionately high risk for cardiovascular disease mediated by the cardiovascular-kidneymetabolic syndrome. While lifestyle interventions are foundational for promoting heart health, behavioral initiatives alone often fall short in achieving attainable goals. GLP-1 receptor agonists are now FDA approved for treating obesity and diabetes mellitus. Statins are available for treating dyslipidemia to targets in the PREVENT risk calculator in the 2026 guidelines of the American Heart Association (AHA). Low-dose aspirin use is currently recommended for persons at intermediate risk by the American College of Cardiology (ACC). Such use by persons with subclinical coronary atherosclerosis identified by coronary artery calcium scoring (CACS) likely provides enhanced prevention. Incorporating these approaches into the primary care of psychiatric patients may thereby mitigate excess morbidity and mortality due to atherosclerotic cardiovascular disease (ASCVD) associated with psychiatric disorders.
No takes yet. Share an insight, caveat, or question.
Arthur J. Siegel (2026) conducted a review in Psychiatric diagnoses with high risk for cardiovascular disease mediated by cardiovascular-kidney-metabolic syndrome. GLP-1 receptor agonists, statins, low-dose aspirin, and coronary artery calcium scoring (CACS) was evaluated on Morbidity and mortality due to atherosclerotic cardiovascular disease (ASCVD). Incorporating GLP-1 receptor agonists, statins, low-dose aspirin, and coronary artery calcium scoring into psychiatric primary care may mitigate excess ASCVD morbidity and mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: